Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VES001 in presymptomatic GRN-frontotemporal dementia
NL-OMON60591Phase 1Completed
- Sponsor
- Vesper Bio
- Start
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1 trial of VES001 in frontotemporal dementia (FTD), sponsored by Vesper Bio. Primary endpoint: Primary endpoint(s). Started Dec 2024; status: completed.
02
Drugs
VES001
03
Conditions
frontotemporal dementia (FTD)
Beyond the preview
Go deeper on NL-OMON60591.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60591.